Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1
Abstract In the present study, reduced toxicity (FluBu3) and myeloablative (BuCy) conditioning were compared in patients with AML who received first allogeneic HSCT in MRD-negative CR1. The study included 124 adult patients who underwent HSCT from an HLA-matched (8/8) sibling, unrelated, or 1-locus mismatched (7/8) unrelated donor (MMUD). The median age was 45 years and intermediate cytogenetics comprised majority (71.8%). The 2-year OS, RFS, CIR and NRM for BuCy (n = 78, 62.9%) and FluBu3 (n = 46, 37.1%) groups were 78.3% and 84.5% (p = 0.358), 78.0% and 76.3% (p = 0.806), 7.7% and 21.5% (p = 0.074) and 14.3% and 2.2% (p = 0.0324), respectively. At the time of data cut-off, relapse and NRM were the main causes of HSCT failure in each of the FluBu3 and BuCy arms. Among patients, 75% of relapsed FluBu3 patients had high-risk features of either poor cytogenetics or FLT3-ITD mutation compared with 16.7% of BuCy patients. The majority of NRM in the BuCy group was due to GVHD (73%), half of whom received MMUD transplantation. To conclude, the FluBu3 reduced toxicity conditioning showed comparable post-transplant OS and RFS to BuCy and was associated with significantly reduced NRM that was offset by a trend towards higher risk of relapse even in MRD-negative CR1 population..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ResearchSquare.com - (2024) vom: 05. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Hee-Je [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-3586986/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA04155650X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA04155650X | ||
| 003 | DE-627 | ||
| 005 | 20240306130953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231116s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-3586986/v1 |2 doi | |
| 035 | |a (DE-627)XRA04155650X | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-3586986/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Hee-Je |e verfasserin |0 (orcid)0000-0003-4098-3366 |4 aut | |
| 245 | 1 | 0 | |a Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract In the present study, reduced toxicity (FluBu3) and myeloablative (BuCy) conditioning were compared in patients with AML who received first allogeneic HSCT in MRD-negative CR1. The study included 124 adult patients who underwent HSCT from an HLA-matched (8/8) sibling, unrelated, or 1-locus mismatched (7/8) unrelated donor (MMUD). The median age was 45 years and intermediate cytogenetics comprised majority (71.8%). The 2-year OS, RFS, CIR and NRM for BuCy (n = 78, 62.9%) and FluBu3 (n = 46, 37.1%) groups were 78.3% and 84.5% (p = 0.358), 78.0% and 76.3% (p = 0.806), 7.7% and 21.5% (p = 0.074) and 14.3% and 2.2% (p = 0.0324), respectively. At the time of data cut-off, relapse and NRM were the main causes of HSCT failure in each of the FluBu3 and BuCy arms. Among patients, 75% of relapsed FluBu3 patients had high-risk features of either poor cytogenetics or FLT3-ITD mutation compared with 16.7% of BuCy patients. The majority of NRM in the BuCy group was due to GVHD (73%), half of whom received MMUD transplantation. To conclude, the FluBu3 reduced toxicity conditioning showed comparable post-transplant OS and RFS to BuCy and was associated with significantly reduced NRM that was offset by a trend towards higher risk of relapse even in MRD-negative CR1 population. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Park, Silvia |4 aut | |
| 700 | 1 | |a Bang, Su-Yeon |4 aut | |
| 700 | 1 | |a Kwag, Daehun |4 aut | |
| 700 | 1 | |a Min, Gi June |4 aut | |
| 700 | 1 | |a Park, Sung-Soo |0 (orcid)0000-0002-8826-4136 |4 aut | |
| 700 | 1 | |a Yoon, Jae-Ho |0 (orcid)0000-0002-2145-9131 |4 aut | |
| 700 | 1 | |a Lee, Sung-Eun |0 (orcid)0000-0002-9810-2050 |4 aut | |
| 700 | 1 | |a Cho, Byung-Sik |0 (orcid)0000-0002-4524-6616 |4 aut | |
| 700 | 1 | |a Eom, Ki-Seong |4 aut | |
| 700 | 1 | |a Kim, Yoo-Jin |4 aut | |
| 700 | 1 | |a Lee, Seok |0 (orcid)0000-0002-9442-9814 |4 aut | |
| 700 | 1 | |a Min, Chang-Ki |4 aut | |
| 700 | 1 | |a Cho, Seok-Goo |0 (orcid)0000-0002-5429-4839 |4 aut | |
| 700 | 1 | |a Lee, Jong Wook |0 (orcid)0000-0003-2949-4166 |4 aut | |
| 700 | 1 | |a Lee, Jong Hyuk |0 (orcid)0000-0001-8465-2791 |4 aut | |
| 700 | 1 | |a Yahng, Seung-Ah |4 aut | |
| 700 | 1 | |a Kim, Tong Yoon |4 aut | |
| 700 | 1 | |a Jeon, Youngwoo |0 (orcid)0000-0003-3362-8200 |4 aut | |
| 700 | 1 | |a Lee, Joon yeop |4 aut | |
| 700 | 1 | |a Shin, Seung-Hwan |0 (orcid)0000-0002-8472-7041 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2024) vom: 05. März |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:03 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41409-024-02255-w |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-3586986/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 03 | ||